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OBJECTIVES This study was designed to quantify the prevalence of abnormal glucose tolerance and insulin
resistance in patients with idiopathic dilated cardiomyopathy (IDCM).
BACKGROUND Insulin resistance is an independent risk factor for mortality in patients with heart failure
(HF) and is a known risk factor for ischemic cardiomyopathy. Though potential physiologic
links between insulin resistance and HF have been hypothesized, the relationship between
insulin resistance and IDCM remains unclear.
METHODS A total of 230 consecutive patients from a university HF clinic were screened for IDCM, the
absence of diabetes mellitus, and the lack of significant co-morbid conditions. Oral glucose
tolerance tests were performed in the 43 patients with IDCM who met these criteria, and
their plasma glucose and insulin responses were compared with those of 40 healthy volunteers,
matched for age, gender, and body mass index.
RESULTS Plasma glucose responses were higher during the oral glucose tolerance tests in patients with
IDCM (p  0.01), associated with significantly higher plasma insulin concentrations
following the oral glucose challenge (p  0.01). In addition, abnormalities of glucose
tolerance were significantly (p 0.05) more common in patients with IDCM (49% vs. 23%).
CONCLUSIONS Insulin resistance and abnormal glucose tolerance are more prevalent in patients with IDCM
and represent potentially reversible metabolic derangements in these individuals. (J Am
Coll Cardiol 2004;44:78–81) © 2004 by the American College of Cardiology Foundationi
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cesistance to insulin-mediated glucose disposal and com-
ensatory hyperinsulinemia predicts the development of
ype 2 diabetes mellitus in individuals with normal glucose
olerance (1–6). However, the ability of insulin-resistant
ndividuals to maintain glucose homeostasis by secreting
arge amounts of insulin is not an unqualified victory, and it
s now clear that insulin resistance represents the central
omponent of a common syndrome that links major cardio-
ascular disease risk factors (1,2,7,8).
Vascular disease severe enough to cause ischemic cardio-
yopathy is commonly associated with diabetes mellitus,
nd a causal link is now well established (9). However, many
atients develop heart failure (HF) without manifest diabe-
es or vascular disease, and these patients are often classified
s having “non-ischemic cardiomyopathy” or “idiopathic
ilated cardiomyopathy” (IDCM). Included in this group
re patients who may have been diagnosed with “diabetic
ardiomyopathy” (9–14). The possibility that insulin resis-
ance, in the absence of frank hyperglycemia, can be a
ontributing factor to the development of IDCM has not
een carefully evaluated. The current study was initiated to
ddress this issue and represents an effort to test the
ypothesis that minor degrees of glucose intolerance and
From the *Division of Cardiovascular Medicine, Stanford University School of
edicine, Stanford, California; †Department of Cardiovascular Medicine, Cleveland
linic Foundation, Cleveland, Ohio; ‡Division of Cardiology, Cedars-Sinai Medical
enter, Los Angeles, California; and the §Division of Endocrinology and Metabo-
ism, Stanford University School of Medicine, Stanford, California.
Manuscript received September 22, 2003; revised manuscript received January 21,e004, accepted March 11, 2004.nsulin resistance are more prevalent in patients with IDCM
n the absence of manifest diabetes. Confirmation of this
ormulation would provide insight into the pathophysiology
f IDCM and serve as a basis for new approaches to its
reatment.
ETHODS
he records of 230 consecutive medically stable outpatients
rom the Stanford University Heart Failure Clinic were
eviewed, the majority of whom had been referred for
onsideration of cardiac transplantation. A total of 104
atients were diagnosed with IDCM on the basis of left
entricular systolic dysfunction (left ventricular ejection
raction 30%) in the absence of coronary artery disease
CAD) either on angiography or in the patients’ history. Of
hese, 20 patients (19%) had been diagnosed with type 2
iabetes and were excluded from further study. Patients
ere excluded if they had significant renal (serum creatinine
1.9 mg/dl), hepatic, pituitary, or adrenal disease. Patients
ere also excluded if they had another known cause for their
F (valvular disease, anthracycline-associated, familial,
ongenital, or alcohol/drug abuse). All patients were New
ork Heart Association functional class II or III.
The remaining 69 patients were contacted, and 43 vol-
nteered for this study. In addition, data from 40 healthy
ndividuals who had volunteered during the same time span
or unrelated studies of insulin resistance were used for
omparison. The demographic characteristics of the two
xperimental groups are given in Table 1, and they are
s
(
s
a
t
C
d
S
p
1
a
a
a
f
(
g
p
t
g
m

c
t
t
S
t
p
w
R
F
o
g
p
w
0
o
c
t
m
g
m
(
0
m
h
t
F
f
p
79JACC Vol. 44, No. 1, 2004 Witteles et al.
July 7, 2004:78–81 Insulin Resistance in Idiopathic Cardiomyopathyimilar in terms of age, gender distribution, body mass index
BMI), and fasting plasma glucose concentrations. The
tudy group had a large standard deviation for BMI, largely
ttributable to one patient with a BMI of 52.5 kg/m2. All
esting was performed in the Stanford University General
linical Research Center after informed consent in accor-
ance with the Investigational Review Board and Human
ubjects Use Committee.
An oral glucose tolerance test was performed on all 83
articipants in the morning after an overnight fast of 10 to
2 h. Blood was taken before and 30, 60, 120, and 180 min
fter a 75 g oral glucose challenge, plasma separated, and stored
t 80°C until measurements were made of plasma glucose
nd insulin concentrations as described previously (15).
Abnormalities of glucose tolerance were defined by the
ollowing criteria of the American Diabetes Association
16): impaired fasting glucose (IFG) as a fasting plasma
lucose concentration between 110 and 125 mg/dl, im-
aired glucose tolerance (IGT) as a plasma glucose concen-
ration between 140 and 199 mg/dl 120 min after the oral
lucose challenge, and a provisional diagnosis of diabetes
ellitus (pDM) as a fasting plasma glucose concentration
125 mg/dl or 200 mg/dl 120 min after the oral glucose
hallenge.
The total integrated glucose and insulin responses during
he oral glucose tolerance test were calculated by the
rapezoidal method, and the two groups were compared by
tudent t test. The Student t test was also used to compare
he baseline clinical characteristics of the two groups; the
revalence of states of glucose intolerance in the two groups
as compared by chi-square analysis.
ESULTS
igure 1 illustrates the plasma glucose and insulin responses
f the two experimental groups before and after the oral
lucose challenge. The results in the top panel show that
Abbreviations and Acronyms
BMI  body mass index
CAD  coronary artery disease
CHF  congestive heart failure
HF  heart failure
IDCM  idiopathic dilated cardiomyopathy
IFG  impaired fasting glucose
IGT  impaired glucose tolerance
pDM  provisional diagnosis of diabetes mellitus
Table 1. Baseline Characteristics of the Two G
IDCM
(n  43)
Age (yrs) 50  12 (21–75
Gender (M/F) 28/15
BMI (kg/m2) 29.6  6.8 (21.3–
Fasting glucose (mg/dl) 105  17 (82–17BMI  body mass index; IDCM  idiopathic dilated cardiomyoplasma glucose concentrations after the oral glucose load
ere significantly higher in the patients with IDCM (p 
.01). Although the fasting plasma glucose concentrations
f the two groups did not differ, both the plasma glucose
oncentration 120 min after the oral glucose challenge and
he total integrated glucose response (413 mg/dl per 180
in vs. 359 mg/dl per 180 min, p 0.01) were significantly
reater in those with IDCM.
The two groups were even more dissimilar in measure-
ents of insulin, with the total integrated insulin response
172 U/ml per 180 min vs. 131 U/ml per 180 min, p 
.01) and the plasma insulin concentration before and 120
in after the oral glucose challenge all being significantly
igher in patients with IDCM (Fig. 1).
In addition to having higher plasma glucose concentra-
ions in response to the oral glucose challenge, the preva-
s
Controls
(n  40) p value
50  11 (19–67) NS
26/14 NS
29.3  4.6 (18.7–37.2) NS
100  10 (81–124) NS
igure 1. Glucose and insulin versus time after oral glucose tolerance test
or study population and controls. Diamonds  controls; squares  study
opulation.roup
)
52.5)
6)athy; NS  not significant.
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Insulin Resistance in Idiopathic Cardiomyopathy July 7, 2004:78–81ence of clinical states of glucose intolerance was greater in
he patients with IDCM. This comparison is shown in
able 2, where 21 of the 43 patients with IDCM (49%) had
ome degree of glucose intolerance as indicated by the
iagnosis of IFG (n  3), IGT (n  12), or pDM (n  6).
y comparison, only 28% of the non-CHF control patients
ad evidence of glucose intolerance (p  0.05). The
revalence of glucose intolerance was not only increased in
atients with IDCM, but the abnormalities present were of
reater magnitude; 18 of the 21 patients with IDCM with
bnormalities of glucose tolerance had either IGT or pDM,
hereas evidence of glucose intolerance in 8 of the 11
ontrol subjects was limited to IFG.
ISCUSSION
he results of this study provide strong evidence that
lucose intolerance is a common characteristic of patients
ith IDCM. At the simplest level, plasma glucose concen-
rations were significantly higher in response to the oral
lucose challenge in patients with IDCM. In addition,
20% of the patients with IDCM who met all the other
nclusion criteria for this study were excluded because they
ad already been diagnosed as having type 2 diabetes.
inally, approximately half of the individuals with IDCM
ho were enrolled in the study were shown to have either
FG, IGT, or pDM by the criteria of the American
iabetes Association (16), a significantly greater prevalence
han was seen in the control population.
Parenthetically, it should be remembered that although
he two groups were not different in terms of age, gender,
nd BMI, the control group was not a random selection of
he population at large, but individuals who had volunteered
or studies of insulin resistance. Thus, it is highly likely that
he control group was enriched with individuals who con-
idered themselves to be at increased risk to be insulin
esistant. Although the study group also consisted of vol-
nteers, most of the consecutive patients from our HF clinic
ho were eligible entered the study. Consequently, the
pproximate doubling of states of glucose intolerance in
atients with IDCM was, if anything, an underestimate of
he magnitude of abnormalities of glucose tolerance present
n these patients.
Some patients in the study population were receiving
edications that could alter insulin sensitivity, though most
f these medications (angiotensin-converting enzyme inhib-
tors, angiotensin receptor blockers, carvedilol, and statins)
able 2. Glucose Tolerance Status of the Two Experimental
roups (p  0.05)
Normal IFG IGT pDM
%
Abnormal
DCM 22 3 12 6 49% (21/43)
ontrol 29 8 3 0 28% (11/40)
DCM  idiopathic dilated cardiomyopathy; IFG  impaired fasting glucose; IGT
impaired glucose tolerance; pDM  provisional diagnosis of diabetes mellitus.ctually improve insulin sensitivity (17–22). tIn addition to being glucose intolerant, patients with
DCM were hyperinsulinemic. Although we did not quan-
ify insulin-mediated glucose disposal in this study, the
ombination of glucose intolerance and hyperinsulinemia
trongly suggests that patients with IDCM were also insulin
esistant (1,2). More specifically, we have shown in a recent
tudy of 490 individuals that the total integrated insulin
esponse to a 75 g oral glucose load was highly correlated
r  0.8) with a specific measure of insulin-mediated
lucose disposal (15) and was a better predictor than either
he fasting insulin concentration or the homeostatic model
ssessment (r  0.6). Consequently, we feel safe in con-
luding that the prevalence of insulin resistance, compen-
atory hyperinsulinemia, and glucose intolerance is signifi-
antly increased in patients with IDCM.
Although the prevalence of glucose intolerance was in-
reased in patients with IDCM, the patients were not
rankly hyperglycemic, and the fasting plasma glucose con-
entrations of the two groups were not significantly differ-
nt. Given the mild degree of plasma glucose elevations in
atients with IDCM, the notion that the cardiomyopathy
esulted from an untoward effect of hyperglycemia per se (as
pposed to insulin resistance itself) can be questioned.
ndeed, the fact that insulin resistance (1,2) and day-long
yperinsulinemia (23) are present in the majority of patients
ith type 2 diabetes raises the possibility that IDCM and
iabetic cardiomyopathy share a common pathogenesis, related
n some manner to insulin resistance/hyperinsulinemia.
The possibility that insulin resistance and compensatory
yperinsulinemia may play a casual role in the development
f IDCM and diabetic cardiomyopathy has important
linical implications. In patients with diabetes, improved
lycemic control, which decreases insulin resistance (24),
an prevent the development of systolic dysfunction (25).
nsulin resistance may predate the development of HF by 20
ears or more (26). Treatment of impaired glucose metab-
lism has been shown to actually reverse systolic dysfunction
n animal models (27). Furthermore, recent preliminary
nvestigations by our group have demonstrated that HF
atients with insulin resistance or frank diabetes may
epresent a subgroup of patients who are more likely to have
reater response to beta-adrenergic blockade than those
ith normal insulin and glucose metabolism, regardless of
he etiology of their HF.
On the other hand, it could be argued that HF leads to
nsulin resistance, rather than vice versa. Swan et al. dem-
nstrated that patients with HF with and without CAD
ere found to be insulin resistant compared with non-HF
ontrols (28). Notably, only the presence of HF (regardless
f CAD status) was found to be independently predictive of
nsulin resistance, despite the fact that patients with CAD
ended to be more insulin resistant than those without
AD. In a longitudinal study of patients with HF second-
ry to valvular disease, Paolisso et al. (29) extensively
valuated the relationship between HF and insulin resis-
ance. These investigators demonstrated that increasing
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July 7, 2004:78–81 Insulin Resistance in Idiopathic Cardiomyopathyeverity of insulin resistance was related to worsened HF
nd decreased survival time. Importantly, this link between
nsulin resistance and worsened survival was independent of
ther measured variables, including peak oxygen consump-
ion. Although these results provide further evidence of an
ssociation between HF and insulin resistance, the causal
ature of the relationship remains elusive and will remain so
ntil appropriate clinical studies are performed.
In conclusion, the results presented provide substantial
vidence that the prevalences of insulin resistance, glucose
ntolerance, and hyperinsulinemia are increased in patients
ith IDCM. Because insulin resistance represents a poten-
ially reversible metabolic derangement, its identification
ay hold potential importance in the treatment of HF,
ither to better guide therapy or to aim for disease stabili-
ation or regression.
eprint requests and correspondence: Dr. Michael B. Fowler,
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tanford University School of Medicine, Falk CVRC 295, Stan-
ord, California 94305-5406. E-mail: mfowler@stanford.edu.
EFERENCES
1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human
disease. Diabetes 1988;37:1595–607.
2. Reaven GM. Pathophysiology of insulin resistance in human disease.
Physiol Rev 1995;75:473–86.
3. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK.
Incidence of type II diabetes in Mexican Americans predicted by
fasting insulin and glucose levels, obesity, and body-fat distribution.
Diabetes 1990;39:283–8.
4. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow
glucose removal rate and hyperinsulinemia precede the development of
type II diabetes in the offspring of the diabetic parents. Ann Intern
Med 1990;113:909–15.
5. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin
secretory dysfunction as precursors of non-insulin-dependent diabetes
mellitus. N Engl J Med 1993;329:1988–92.
6. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. Relation-
ships between insulin secretion, insulin action, and fasting plasma
glucose concentration in nondiabetic and noninsulin-dependent dia-
betic subjects. J Clin Invest 1984;74:1238–46.
7. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syn-
drome and total and cardiovascular disease mortality in middle-aged
men. JAMA 2002;288:2709–16.
8. National Institutes of Health. Third report on the National Choles-
terol Education Program Expert Panel on Detection, Evaluation and
Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III). Bethesda, MD: National Institute of Health, NIH Publi-
cation 01-3670, 2001.
9. Zoneraich S. Ischemic heart disease and diabetic cardiomyopathy.
J Am Coll Cardiol 1989;14:1585–6.
0. Regan TJ, Ahmed S, Haider B, Moschos C, Weisse A. Diabetic
cardiomyopathy: experimental and clinical observations. N J Med
1994;91:776–8.1. Zarich SW, Nesto RW. Diabetic cardiomyopathy. Am Heart J
1989;118:1000–12.
2. Bell DS. Diabetic cardiomyopathy. A unique entity or a complication
of coronary artery disease? Diabetes Care 1995;18:708–14.
3. Hu XD, Peng XJ, Zhang CT. [Diabetic myocardiopathy]. Zhonghua
Nei Ke Za Zhi 1994;33:18–20.
4. Asmal AC, Leary WP, Thandroyen F. Diabetic heart disease. S Afr
Med J 1980;57:788–90.
5. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relation-
ship between several surrogate estimates of insulin resistance and
quantification of insulin-mediated glucose disposal in 490 healthy
nondiabetic volunteers. Diabetes Care 2000;23:171–5.
6. Report of the Expert Committee on the Diagnosis and Classification
of Diabetes Mellitus. Diabetes Care 1997;20:1183–97.
7. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development
of diabetes mellitus: evidence for a protective treatment effect in the
West of Scotland Coronary Prevention Study. Circulation 2001;103:
357–62.
8. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-
converting-enzyme inhibition compared with convention therapy on
cardiovascular morbidity and mortality in hypertension: the Captopril
Prevention Project (CAPP) randomized trial. Lancet 1999;353:611–6.
9. Wright JT. Major outcomes in high-risk hypertensive patients ran-
domized to angiotensin-converting enzyme inhibitor or calcium chan-
nel blocker vs diuretic: the Antihypertensive and Lipid-Lowering
treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002;
288:2981–97.
0. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of
an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascu-
lar events in high-risk patients. The Heart Outcomes Prevention
Evaluation Study Investigators. N Engl J Med 2000;342:145–53.
1. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity
and mortality in the Losartan Intervention For Endpoint reduction in
hypertension study (LIFE): a randomised trial against atenolol. Lancet
2002;359:995–1003.
2. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on
mortality and morbidity in patients with chronic heart failure: the
CHARM-Overall programme. Lancet 2003;362:759–66.
3. Reaven GM, Chen YD, Hollenbeck CB, Sheu WH, Ostrega D,
Polonsky KS. Plasma insulin, C-peptide, and proinsulin concentra-
tions in obese and nonobese individuals with varying degrees of glucose
tolerance. J Clin Endocrinol Metab 1993;76:44–8.
4. Andrews WJ, Vasquez B, Nagulesparan M, et al. Insulin therapy in
obese, non-insulin-dependent diabetes induces improvements in insu-
lin action and secretion that are maintained for two weeks after insulin
withdrawal. Diabetes 1984;33:634–42.
5. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart
failure among adult patients with diabetes. Circulation 2001;103:
2668–73.
6. Arnlov J, Lind L, Zethelius B, et al. Several factors associated with the
insulin resistance syndrome are predictors of left ventricular systolic
dysfunction in a male population after 20 years of follow-up. Am
Heart J 2001;142:720–4.
7. Stroedter D, Schmidt T, Bretzel RG, Federlin K. Glucose metabolism
and left ventricular dysfunction are normalized by insulin and islet
transplantation in mild diabetes in the rat. Acta Diabetol 1995;32:
235–43.
8. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic
heart failure: relation to severity and etiology of heart failure. J Am
Coll Cardiol 1997;30:527–32.
9. Paolisso G, Tagliamonte MR, Rizzo MR, et al. Prognostic importance
of insulin-mediated glucose uptake in aged patients with congestive
heart failure secondary to mitral and/or aortic valve disease. Am J
Cardiol 1999;83:1338–44.
